ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization
- PMID: 20142362
- DOI: 10.4049/jimmunol.0901445
ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization
Abstract
Accumulating evidence suggests that the dichotomy between tolerance and active IgA immunity in mucosal immune responses is regulated at the APC level. Therefore, immunomodulation of the APC could be an effective mechanism to control the two response patterns. In this study, we demonstrate that ADP-ribosylation controls the outcome of tolerance or active effector T cell immunity to an internal peptide p323-339 from OVA inserted into the cholera toxin (CT)-derived CTA1-OVA-DD adjuvant. We found that a single point mutation, CTA1R7K-OVA-DD, resulting in lack of enzymatic activity, promoted peptide-specific tolerance in TCR transgenic CD4(+) T cells following a single intranasal (i.n.) treatment. The CTA1R7K-OVA-DD-induced tolerance was strong, long-lasting, and impaired the ability of adoptively transferred naive peptide-specific CD4(+) T cells to respond to Ag-challenge, irrespective if this was given i.p or i.n. The tolerance correlated with induction of regulatory T cells of the regulatory T type 1 characterized by CD25(-)Foxp3(-)CD4(+) T cells producing IL-10. In contrast, in IL-10-deficient mice, no peptide-specific tolerance was observed, and these mice exhibited unimpaired CD4(+) T cell responsiveness to recall Ag irrespective of if they were untreated (PBS) or treated i.n. with CTA1R7K-OVA-DD. Thus, for the first time, we can provide unequivocal proof that ADP-ribosylation can control the outcome of mucosal Ag exposure from tolerance to an enhanced effector CD4(+) T cell response. The exploitation of this system for clinical treatment of autoimmune diseases is discussed.
Similar articles
-
ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.Ann N Y Acad Sci. 2004 Dec;1029:193-208. doi: 10.1196/annals.1309.036. Ann N Y Acad Sci. 2004. PMID: 15681758 Review.
-
Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.Arthritis Rheum. 2009 Jun;60(6):1672-82. doi: 10.1002/art.24566. Arthritis Rheum. 2009. PMID: 19479868
-
Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions.Scand J Immunol. 2006 Sep;64(3):251-9. doi: 10.1111/j.1365-3083.2006.01823.x. Scand J Immunol. 2006. PMID: 16918694
-
Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.Gastroenterology. 2007 Aug;133(2):517-28. doi: 10.1053/j.gastro.2007.04.073. Epub 2007 May 3. Gastroenterology. 2007. PMID: 17681173
-
From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.Immunol Lett. 2005 Mar 15;97(2):193-8. doi: 10.1016/j.imlet.2004.12.008. Epub 2005 Jan 19. Immunol Lett. 2005. PMID: 15752558 Review.
Cited by
-
Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseases.Front Immunol. 2013 Aug 20;4:245. doi: 10.3389/fimmu.2013.00245. eCollection 2013. Front Immunol. 2013. PMID: 23970886 Free PMC article.
-
Cholera-like enterotoxins and Regulatory T cells.Toxins (Basel). 2010 Jul;2(7):1774-95. doi: 10.3390/toxins2071774. Epub 2010 Jul 6. Toxins (Basel). 2010. PMID: 22069660 Free PMC article. Review.
-
Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model.Clin Exp Immunol. 2015 Apr;180(1):28-39. doi: 10.1111/cei.12487. Clin Exp Immunol. 2015. PMID: 25393803 Free PMC article.
-
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Vaccine. 2010 Oct 4;28(42):6901-14. doi: 10.1016/j.vaccine.2010.08.006. Epub 2010 Aug 17. Vaccine. 2010. PMID: 20723629 Free PMC article.
-
Recent progress in mucosal vaccine development: potential and limitations.Nat Rev Immunol. 2012 Jul 25;12(8):592-605. doi: 10.1038/nri3251. Nat Rev Immunol. 2012. PMID: 22828912 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous